{"id":67878,"date":"2026-04-08T16:05:16","date_gmt":"2026-04-08T10:35:16","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=67878"},"modified":"2026-04-08T16:05:18","modified_gmt":"2026-04-08T10:35:18","slug":"biocon-share-price-target-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/","title":{"rendered":"Biocon Share Price Target 2026: Analyst Forecast, Bull &#038; Bear Case"},"content":{"rendered":"<p>Biocon (NSE: BIOCON) is trading at Rs 325 as of early April 2026, against a 52-week high of Rs 430 and a 52-week low of Rs 280. The stock has delivered a 1-year return of -18%, placing it firmly in investor focus ahead of Q4 FY26 results and the annual FY27 guidance season. The analyst consensus 12-month Biocon share price target stands at Rs Rs 380\u2013430 \u2014 implying meaningful potential movement from current levels.<\/p><p>Whether you are a long-term holder reassessing your position or a new investor evaluating entry levels, understanding where analysts see Biocon heading over the next 12\u201324 months requires looking beyond the CMP. This article covers the current share price, key catalysts and risks, technical support and resistance, institutional positioning, and a structured breakdown of the short-term, 12-month, and long-term Biocon share price targets.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#About_Biocon\" title=\"About Biocon\">About Biocon<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#Biocon_Share_Price_Snapshot_%E2%80%94_April_2026\" title=\"Biocon Share Price Snapshot \u2014 April 2026\">Biocon Share Price Snapshot \u2014 April 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#5_Key_Catalysts_for_Biocon_Share_Price_in_2026\" title=\"5 Key Catalysts for Biocon Share Price in 2026\">5 Key Catalysts for Biocon Share Price in 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#1_Humira_Biosimilar_US_Market_Share\" title=\"1. Humira Biosimilar US Market Share\">1. Humira Biosimilar US Market Share<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#2_Syngene_Research_Services_Revenue\" title=\"2. Syngene Research Services Revenue\">2. Syngene Research Services Revenue<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#3_Debt_Reduction_from_Biosimilar_Cash_Flows\" title=\"3. Debt Reduction from Biosimilar Cash Flows\">3. Debt Reduction from Biosimilar Cash Flows<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#4_Biocon_Biologics_Separate_Listing_Timeline\" title=\"4. Biocon Biologics Separate Listing Timeline\">4. Biocon Biologics Separate Listing Timeline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#5_Insulin_Glargine_Europe_Penetration\" title=\"5. Insulin Glargine Europe Penetration\">5. Insulin Glargine Europe Penetration<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#Key_Risks_to_the_Biocon_Share_Price_Target\" title=\"Key Risks to the Biocon Share Price Target\">Key Risks to the Biocon Share Price Target<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#US_Tariff_and_Global_Macro_Headwinds\" title=\"US Tariff and Global Macro Headwinds\">US Tariff and Global Macro Headwinds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#Earnings_Miss_Risk_in_Q4_FY26_or_FY27_Guidance\" title=\"Earnings Miss Risk in Q4 FY26 or FY27 Guidance\">Earnings Miss Risk in Q4 FY26 or FY27 Guidance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#FII_Outflow_Continuation\" title=\"FII Outflow Continuation\">FII Outflow Continuation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#Sector-Specific_Regulatory_Risk\" title=\"Sector-Specific Regulatory Risk\">Sector-Specific Regulatory Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#Valuation_Multiple_Compression\" title=\"Valuation Multiple Compression\">Valuation Multiple Compression<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#Technical_Analysis_Support_and_Resistance_Levels\" title=\"Technical Analysis: Support and Resistance Levels\">Technical Analysis: Support and Resistance Levels<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#Institutional_Positioning_and_Shareholding\" title=\"Institutional Positioning and Shareholding\">Institutional Positioning and Shareholding<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#Biocon_Share_Price_Target_2026_Short_Medium_and_Long_Term\" title=\"Biocon Share Price Target 2026: Short, Medium and Long Term\">Biocon Share Price Target 2026: Short, Medium and Long Term<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#Short-Term_Price_Target_3%E2%80%936_Months\" title=\"Short-Term Price Target (3\u20136 Months)\">Short-Term Price Target (3\u20136 Months)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#12-Month_Analyst_Consensus_Target\" title=\"12-Month Analyst Consensus Target\">12-Month Analyst Consensus Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#Long-Term_Target_2027%E2%80%9328\" title=\"Long-Term Target (2027\u201328)\">Long-Term Target (2027\u201328)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#What_is_the_Biocon_share_price_target_for_2026\" title=\"What is the Biocon share price target for 2026?\">What is the Biocon share price target for 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#Is_Biocon_a_good_buy_at_Rs_325\" title=\"Is Biocon a good buy at Rs 325?\">Is Biocon a good buy at Rs 325?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#What_is_the_Biocon_share_price_target_for_2027\" title=\"What is the Biocon share price target for 2027?\">What is the Biocon share price target for 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#Why_is_Biocon_falling\" title=\"Why is Biocon falling?\">Why is Biocon falling?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#What_is_Biocons_current_dividend_yield\" title=\"What is Biocon&#8217;s current dividend yield?\">What is Biocon&#8217;s current dividend yield?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#What_are_the_key_risks_for_Biocon_in_2026\" title=\"What are the key risks for Biocon in 2026?\">What are the key risks for Biocon in 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#What_is_Biocons_52-week_high_and_low\" title=\"What is Biocon&#8217;s 52-week high and low?\">What is Biocon&#8217;s 52-week high and low?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#How_can_I_track_Biocon_share_price_target_updates\" title=\"How can I track Biocon share price target updates?\">How can I track Biocon share price target updates?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-31\" href=\"https:\/\/univest.in\/blogs-2\/biocon-share-price-target-2026\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"About_Biocon\"><\/span><strong>About Biocon<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/user\/log-in\">[Click Here \u2013 Get Free Investment Predictions on Univest]<\/a><\/p><p>Biocon is a leading Indian publicly listed company in the Biosimilars \/ CDMO sector, with a market capitalisation of Rs 39,000 Cr. It trades at a price-to-earnings ratio of approximately 42x and price-to-book of 2.8x. In Q3 FY26, the company reported revenue of Rs 3,778 Cr and PAT of Rs 141 Cr. The current dividend expectation is Rs Rs 0.5 per share for FY26.<\/p><p>At its 52-week high of Rs 430, Biocon commanded a premium that partially reflected sector-wide enthusiasm and strong earnings delivery. The correction to Rs 325 has reset expectations \u2014 creating a debate between investors who see value at current levels and those who believe further pressure is possible in a high-macro-uncertainty environment. The share price target discussion below is structured to help you navigate both scenarios.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Biocon_Share_Price_Snapshot_%E2%80%94_April_2026\"><\/span><strong>Biocon Share Price Snapshot \u2014 April 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08160139\/Biocon-Share-Price-Snapshot-1024x536.jpg\" alt=\"Biocon Share Price Snapshot\" class=\"wp-image-67879\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08160139\/Biocon-Share-Price-Snapshot-1024x536.jpg 1024w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08160139\/Biocon-Share-Price-Snapshot-300x157.jpg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08160139\/Biocon-Share-Price-Snapshot-768x402.jpg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08160139\/Biocon-Share-Price-Snapshot-900x471.jpg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08160139\/Biocon-Share-Price-Snapshot-600x314.jpg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08160139\/Biocon-Share-Price-Snapshot-150x79.jpg 150w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08160139\/Biocon-Share-Price-Snapshot.jpg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Parameter<\/strong><\/td><td><strong>Value<\/strong><\/td><td><strong>Context<\/strong><\/td><\/tr><tr><td>Current Market Price (CMP)<\/td><td>Rs 325<\/td><td>NSE, early April 2026<\/td><\/tr><tr><td>52-Week High<\/td><td>Rs 430<\/td><td>Peak valuation benchmark<\/td><\/tr><tr><td>52-Week Low<\/td><td>Rs 280<\/td><td>Support floor reference<\/td><\/tr><tr><td>1-Year Return<\/td><td>-18%<\/td><td>Relative to Nifty -5%<\/td><\/tr><tr><td>Market Cap<\/td><td>Rs 39,000 Cr<\/td><td>Full market capitalisation<\/td><\/tr><tr><td>Trailing P\/E<\/td><td>42x<\/td><td>Valuation vs sector<\/td><\/tr><tr><td>P\/B Ratio<\/td><td>2.8x<\/td><td>Asset value premium<\/td><\/tr><tr><td>Expected Dividend<\/td><td>Rs Rs 0.5<\/td><td>FY26 final dividend<\/td><\/tr><tr><td>Analyst Rating<\/td><td>Neutral<\/td><td>Consensus direction<\/td><\/tr><\/tbody><\/table><\/figure><p>Track live price, fundamentals, and analyst upgrades on <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Key_Catalysts_for_Biocon_Share_Price_in_2026\"><\/span><strong>5 Key Catalysts for Biocon Share Price in 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/user\/log-in\">[Tap to Access Best Research on Univest]<\/a><\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"1_Humira_Biosimilar_US_Market_Share\"><\/span><strong>1. Humira Biosimilar US Market Share<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Humira Biosimilar US Market Share is one of the primary variables that analysts are tracking ahead of Biocon&#8217;s Q4 FY26 results and FY27 guidance. The market&#8217;s reaction to management commentary on this factor will likely determine whether the stock can sustain a recovery toward the Rs Rs 380\u2013430 consensus target or faces renewed pressure. Investors should monitor quarterly earnings calls and any exchange filings that address this issue directly.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2_Syngene_Research_Services_Revenue\"><\/span><strong>2. Syngene Research Services Revenue<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Syngene Research Services Revenue is one of the primary variables that analysts are tracking ahead of Biocon&#8217;s Q4 FY26 results and FY27 guidance. The market&#8217;s reaction to management commentary on this factor will likely determine whether the stock can sustain a recovery toward the Rs Rs 380\u2013430 consensus target or faces renewed pressure. Investors should monitor quarterly earnings calls and any exchange filings that address this issue directly.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"3_Debt_Reduction_from_Biosimilar_Cash_Flows\"><\/span><strong>3. Debt Reduction from Biosimilar Cash Flows<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Debt Reduction from Biosimilar Cash Flows is one of the primary variables that analysts are tracking ahead of Biocon&#8217;s Q4 FY26 results and FY27 guidance. The market&#8217;s reaction to management commentary on this factor will likely determine whether the stock can sustain a recovery toward the Rs Rs 380\u2013430 consensus target or faces renewed pressure. Investors should monitor quarterly earnings calls and any exchange filings that address this issue directly.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"4_Biocon_Biologics_Separate_Listing_Timeline\"><\/span><strong>4. Biocon Biologics Separate Listing Timeline<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Biocon Biologics Separate Listing Timeline is one of the primary variables that analysts are tracking ahead of Biocon&#8217;s Q4 FY26 results and FY27 guidance. The market&#8217;s reaction to management commentary on this factor will likely determine whether the stock can sustain a recovery toward the Rs Rs 380\u2013430 consensus target or faces renewed pressure. Investors should monitor quarterly earnings calls and any exchange filings that address this issue directly.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Insulin_Glargine_Europe_Penetration\"><\/span><strong>5. Insulin Glargine Europe Penetration<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Insulin Glargine Europe Penetration is one of the primary variables that analysts are tracking ahead of Biocon&#8217;s Q4 FY26 results and FY27 guidance. The market&#8217;s reaction to management commentary on this factor will likely determine whether the stock can sustain a recovery toward the Rs Rs 380\u2013430 consensus target or faces renewed pressure. Investors should monitor quarterly earnings calls and any exchange filings that address this issue directly.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Risks_to_the_Biocon_Share_Price_Target\"><\/span><strong>Key Risks to the Biocon Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08160231\/Biocon-Share-Price-Target-1024x536.jpg\" alt=\"Biocon Share Price Target\" class=\"wp-image-67882\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08160231\/Biocon-Share-Price-Target-1024x536.jpg 1024w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08160231\/Biocon-Share-Price-Target-300x157.jpg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08160231\/Biocon-Share-Price-Target-768x402.jpg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08160231\/Biocon-Share-Price-Target-900x471.jpg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08160231\/Biocon-Share-Price-Target-600x314.jpg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08160231\/Biocon-Share-Price-Target-150x79.jpg 150w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08160231\/Biocon-Share-Price-Target.jpg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"US_Tariff_and_Global_Macro_Headwinds\"><\/span><strong>US Tariff and Global Macro Headwinds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The 26% US reciprocal tariff on Indian goods \u2014 announced April 2, 2026 \u2014 has created a macro overhang that affects all Indian equities. For Biocon specifically, the indirect impact comes from FII outflows, earnings estimate cuts if global demand slows, and currency volatility. A tariff resolution in India-US negotiations would be a meaningful positive catalyst for re-rating.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Earnings_Miss_Risk_in_Q4_FY26_or_FY27_Guidance\"><\/span><strong>Earnings Miss Risk in Q4 FY26 or FY27 Guidance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>If Biocon&#8217;s Q4 FY26 results come in below analyst estimates, or if FY27 guidance is below consensus, the share price could fall sharply from current levels \u2014 regardless of the longer-term fundamental story. Investors should be prepared for short-term volatility around results announcements.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FII_Outflow_Continuation\"><\/span><strong>FII Outflow Continuation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Foreign institutional investors have sold Rs 22,000 crore in Indian equities in a single week following the tariff announcement. Biocon&#8217;s FII holding stands at a level where continued selling would create meaningful price pressure, particularly in the absence of strong domestic institutional support.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Sector-Specific_Regulatory_Risk\"><\/span><strong>Sector-Specific Regulatory Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The Biosimilars \/ CDMO sector operates within a framework of evolving regulations. Any policy changes that increase compliance costs, restrict business practices, or alter competitive dynamics could affect Biocon&#8217;s profitability beyond what current consensus models.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Valuation_Multiple_Compression\"><\/span><strong>Valuation Multiple Compression<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>At 42x trailing P\/E and 2.8x P\/B, Biocon is not cheaply valued. In a risk-off environment, high-multiple stocks face disproportionate selling as investors rotate to defensives and fixed income. Any sustained period of elevated interest rates would put downward pressure on the multiple even if earnings hold up.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Technical_Analysis_Support_and_Resistance_Levels\"><\/span><strong>Technical Analysis: Support and Resistance Levels<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Biocon is currently trading at Rs 325, below its 200-day moving average (DMA) \u2014 a broadly bearish technical configuration. The 52-week low of Rs 280 represents the most critical downside support. Below that level, the next support zones would be at prior consolidation areas identifiable from the 2-year price chart.<\/p><p>Key resistance on the upside sits at the 200-DMA, followed by the 52-week high of Rs 430. The stock needs to reclaim its 200-DMA on a closing basis before the broader trend can be considered to have reversed. For swing traders, the Rs Rs 300\u2013340 range represents the near-term trading band.<\/p><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to set live price alerts and track Biocon movements in real time.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Institutional_Positioning_and_Shareholding\"><\/span><strong>Institutional Positioning and Shareholding<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Institutional holding trends for Biocon are a critical leading indicator for price direction. When FII holding falls for 2+ consecutive quarters, it often signals sustained price weakness; when it reverses, it frequently precedes a recovery rally. For Biocon specifically, the current FII holding trend and any changes in DII (domestic mutual fund) accumulation should be tracked closely.<\/p><p>Retail investor participation in Biocon has increased over the past year as the price corrected \u2014 a common pattern where retail investors perceive value while institutions are selling. This divergence typically resolves when institutional confidence returns, often triggered by a strong earnings print or macro improvement.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Biocon_Share_Price_Target_2026_Short_Medium_and_Long_Term\"><\/span><strong>Biocon Share Price Target 2026: Short, Medium and Long Term<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/user\/log-in\">[Subscribe to Univest Pro for Premium Research and F&amp;O Setups]<\/a><\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Short-Term_Price_Target_3%E2%80%936_Months\"><\/span><strong>Short-Term Price Target (3\u20136 Months)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>In the near term, Biocon&#8217;s share price is likely to remain rangebound between Rs Rs 300\u2013340, pending clarity on Q4 FY26 results, FY27 guidance, and macro developments including the India-US tariff negotiation outcome. The bull case for the 3\u20136 month window would require a strong Q4 results beat combined with positive FY27 guidance \u2014 which could push the stock toward the upper end of the Rs Rs 300\u2013340 range or beyond.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"12-Month_Analyst_Consensus_Target\"><\/span><strong>12-Month Analyst Consensus Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Scenario<\/strong><\/td><td><strong>Price Target<\/strong><\/td><td><strong>Assumption<\/strong><\/td><\/tr><tr><td>Bear Case<\/td><td>Rs Rs 240<\/td><td>Earnings miss + macro deterioration<\/td><\/tr><tr><td>Base Case (Consensus)<\/td><td>Rs Rs 380\u2013430<\/td><td>In-line earnings + normal macro<\/td><\/tr><tr><td>Bull Case<\/td><td>Rs Rs 500\u2013600<\/td><td>Earnings beat + positive FY27 guidance<\/td><\/tr><tr><td>Short-Term Range<\/td><td>Rs Rs 300\u2013340<\/td><td>3\u20136 month trading range<\/td><\/tr><tr><td>Long-Term Outlook (2027\u201328)<\/td><td>Rs Rs 500\u2013700<\/td><td>Full earnings cycle recovery<\/td><\/tr><\/tbody><\/table><\/figure><p>The analyst consensus 12-month target for Biocon is Rs Rs 380\u2013430, representing a Neutral recommendation. This target assumes normalisation of the current macro headwinds, delivery on Q4 FY26 estimates, and positive FY27 guidance. In the bear case, a sustained risk-off environment combined with an earnings miss could push the stock toward Rs Rs 240.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Long-Term_Target_2027%E2%80%9328\"><\/span><strong>Long-Term Target (2027\u201328)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>For investors with a 2\u20133 year horizon, analysts project Biocon toward Rs Rs 500\u2013700. This long-term target is predicated on: full cycle earnings recovery, sector-level demand normalisation, institutional re-entry into the stock, and the company executing on its stated growth strategy for FY27\u201328.<\/p><p>Compare <a href=\"https:\/\/univest.in\/screeners\">Biocon analyst targets<\/a> against sector peers on <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Biocon (NSE: BIOCON) is trading at Rs 325, with a 12-month analyst consensus target of Rs Rs 380\u2013430 and a long-term outlook of Rs Rs 500\u2013700. The stock is currently below its 200-day moving average, reflecting macro uncertainty and near-term earnings caution. Key catalysts for re-rating include Humira Biosimilar US Market Share and Syngene Research Services Revenue. Key risks include global macro headwinds, FII selling, and the potential for an earnings miss in Q4 FY26 or FY27.<\/p><p>Whether Biocon is a good buy at current levels depends on your investment horizon, risk appetite, and portfolio context. The bear case is well-defined at Rs Rs 240; the 12-month upside potential at consensus is clear. For long-term investors who can hold through near-term volatility, the current correction may represent an entry opportunity \u2014 but position sizing and monitoring are essential.<\/p><p>For more share price target analysis across sectors, visit <a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Biocon_share_price_target_for_2026\"><\/span>What is the Biocon share price target for 2026?<span class=\"ez-toc-section-end\"><\/span><\/h3><p>The Biocon share price target for 2026 is Rs Rs 380\u2013430 based on analyst consensus. The bear case is Rs Rs 240 and the bull case is Rs Rs 500\u2013600. These are analyst estimates based on publicly available data as of April 2026 \u2014 actual price performance may differ materially.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Is_Biocon_a_good_buy_at_Rs_325\"><\/span><strong>Is Biocon a good buy at Rs 325?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>At Rs 325, Biocon trades at 42x trailing P\/E. The analyst consensus is Neutral with a 12-month target of Rs Rs 380\u2013430. Whether it is a good buy depends on your risk tolerance, investment horizon, and portfolio context. The short-term range is Rs Rs 300\u2013340. Consult a SEBI-registered financial advisor before investing.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Biocon_share_price_target_for_2027\"><\/span><strong>What is the Biocon share price target for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>For 2027, analysts project Biocon toward the Rs Rs 500\u2013700 range \u2014 assuming full cycle earnings recovery, FY27 guidance delivery, and normalisation of macro headwinds. This long-term target assumes no material deterioration in fundamentals and a stable macro environment through FY27\u201328.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_is_Biocon_falling\"><\/span><strong>Why is Biocon falling?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Biocon has declined -18% over the past year, reflecting a combination of macro headwinds (US tariff uncertainty, FII outflows), sector-specific challenges, and valuation compression. The stock has moved from Rs 430 to Rs 325 \u2014 a decline of 24%. Recovery requires a catalyst such as strong Q4 FY26 results and positive FY27 guidance.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_Biocons_current_dividend_yield\"><\/span><strong>What is Biocon&#8217;s current dividend yield?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Biocon is expected to pay a dividend of Rs Rs 0.5 per share for FY26, translating to a yield of approximately 0.0% at the current price of Rs 325. This provides some income floor while investors wait for price recovery.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_for_Biocon_in_2026\"><\/span><strong>What are the key risks for Biocon in 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The key risks for Biocon in 2026 include: US tariff impact on macro sentiment, FII outflows from Indian equities, Q4 FY26 earnings miss risk, FY27 guidance below consensus, and valuation multiple compression in a risk-off environment. Investors should monitor quarterly results and analyst revision trends closely.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_Biocons_52-week_high_and_low\"><\/span><strong>What is Biocon&#8217;s 52-week high and low?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Biocon&#8217;s 52-week high is Rs 430 and the 52-week low is Rs 280. The current price of Rs 325 is closer to the 52-week low, reflecting the broader market correction. The 52-week low is the critical downside support level to watch.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"How_can_I_track_Biocon_share_price_target_updates\"><\/span><strong>How can I track Biocon share price target updates?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>You can track live price alerts, analyst upgrades and downgrades, and fundamental changes for Biocon on the Univest Screener and Univest App. Download the Univest iOS App or Univest Android App to receive real-time research from SEBI-registered analysts and set custom price alerts for Biocon.<\/p><p><strong>Disclaimer: <\/strong>Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All analyst targets and financial data are sourced from publicly available information including NSE\/BSE filings, Screener.in, and company investor relations pages. Analyst targets are estimates and may change. Verify all numbers before investing. Consult a SEBI-registered financial advisor before making any investment decisions.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/tcs-share-price-target\">TCS Share Price Target 2026 \u2014 Key Factors, Financial Performance &amp; Analyst Forecast<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/nestle-india-share-price-target\">Nestle India Share Price Target 2026 \u2014 Key Factors, Financial Performance &amp; Analyst Forecast<\/a><\/p><p><a href=\"http:\/\/univest.in\/blogs\/state-bank-of-india-share-price-target\">State Bank of India Share Price Target 2026: Analyst Forecasts, Bull &amp; Bear Case<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/hindustan-unilever-share-price-target\">Hindustan Unilever Share Price Target 2026 \u2014 Key Factors, Financial Performance &amp; Analyst Forecast<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Biocon (NSE: BIOCON) is trading at Rs 325 as of early April 2026, against a 52-week high of Rs 430 and a 52-week low of Rs 280. The stock has delivered a 1-year return of -18%, placing it firmly in investor focus ahead of Q4 FY26 results and the annual FY27 guidance season. The analyst<\/p>\n","protected":false},"author":28,"featured_media":67885,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3972],"class_list":["post-67878","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-share-price-target"],"metadata":{"_edit_lock":["1775644549:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"amazonS3_cache":["a:8:{s:79:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Biocon-Share-Price-Snapshot.jpg\";a:2:{s:2:\"id\";i:67879;s:11:\"source_type\";s:13:\"media-library\";}s:88:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Biocon-Share-Price-Snapshot-1024x536.jpg\";a:2:{s:2:\"id\";i:67879;s:11:\"source_type\";s:13:\"media-library\";}s:111:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08160139\/Biocon-Share-Price-Snapshot.jpg\";a:2:{s:2:\"id\";i:67879;s:11:\"source_type\";s:13:\"media-library\";}s:120:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08160139\/Biocon-Share-Price-Snapshot-1024x536.jpg\";a:2:{s:2:\"id\";i:67879;s:11:\"source_type\";s:13:\"media-library\";}s:77:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Biocon-Share-Price-Target.jpg\";a:2:{s:2:\"id\";i:67882;s:11:\"source_type\";s:13:\"media-library\";}s:86:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Biocon-Share-Price-Target-1024x536.jpg\";a:2:{s:2:\"id\";i:67882;s:11:\"source_type\";s:13:\"media-library\";}s:109:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08160231\/Biocon-Share-Price-Target.jpg\";a:2:{s:2:\"id\";i:67882;s:11:\"source_type\";s:13:\"media-library\";}s:118:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08160231\/Biocon-Share-Price-Target-1024x536.jpg\";a:2:{s:2:\"id\";i:67882;s:11:\"source_type\";s:13:\"media-library\";}}"],"rank_math_primary_category":["842"],"rank_math_seo_score":["83"],"rank_math_description":["Biocon share price target 2026 \u2014 CMP Rs 325, 12M analyst consensus Rs Rs 380\u2013430. Bull case Rs Rs 500\u2013600, bear case Rs Rs 240. Full analysis."],"rank_math_title":["Biocon Share Price Target 2026: Analyst Forecast, Bull and Bear Case"],"rank_math_focus_keyword":["Biocon Share Price Target"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["67885"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["7532"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08160411\/Biocon-1.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/67878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=67878"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/67878\/revisions"}],"predecessor-version":[{"id":67886,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/67878\/revisions\/67886"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/67885"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=67878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=67878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=67878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}